jbainseky, again you make my point.
Indeed he said: subgroups or patients characteristics
He didn't say the complete trial, which was exactly what I was aiming for. Kings statement clearly indicates that he is thinking/suspecting that a PORTION of the patients caused this triggering and NOT the main stream and that that is what they are going to give extra attention in there analysis.
And in the end, whatever CEO King might have been thinking is now outdated/obsolete since CEO King's last statement
was not
--> WHAT CAUSED THIS FUTILITY ADVICE
but was
--> WE HAVE statistical significant improvement in overall survival of patients treated with Bavituximab+Docetaxel over patients treated with Placebo+Docetaxel from Sunrise 2nd ln NSCLC.
I think that if the US changes its tax laws it is the last change that is applied and not whatever they did before, isn't it.
The same goes for PPHM. Their last weeks PR is what the current situation is and what has been sufficiently verified to be allowed to bring it on 10 OKT 2016 at ESMO in a presentation form-factor that is reserved by ESMO for late braking presentation of "HIGH QUALITY DATA" (specifically).
So who cares about what CEO King taught in MARCH based on the limited still blinded data of Sunrise if we know what he, this time not THINKS, BUT KNOWS from Sunrise data analysis and is about to make public in less then 6 days?
Market Data 
Markets 
AI
